Hugel has been developing and introducing new technologies based on botulinum toxin manufacturing technology in cooperation with the best researchers at home and abroad, mainly in the field of cosmetic surgery and therapeutics.
Hugel creates new value through continuous management innovation and is evolving into a truly global biopharmaceutical company.VIEW MORE
Hugel has been developing into a truly global biopharmaceutical company by constantly creating new value, and we will continue to lead the way for Korea to become a powerhouse in the bio sector.
Hugel’s ‘Letybo’ First in Korea to Obta..
Hugel Achieves Record-high Quarterly Sa..
Hugel Presents Data from Phase 3 Clinica..
Hugel resubmits BLA for its botulinum t..
Hugel Participates in IMCAS ASIA 2022, ..
Hugel Achieves Record-High Performance ..
We will provide maximum investment value through securing future growth engines.